Humacyte, Inc. (HUMA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.78, representing a -2.32% change from its previous close.
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from its prior day's close.
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
Humacyte, Inc. (HUMA) closed the most recent trading day at $1.03, moving 3.74% from the previous trading session.
Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript
Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know
Humacyte, Inc. (HUMA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Humacyte Q1 Earnings Call Highlights
Humacyte NASDAQ: HUMA reported first-quarter 2026 Symvess sales of $0.5 million and outlined a series of commercial, clinical and cost-reduction initiatives aimed at accelerating adoption of its bioengineered vascular products.
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago.
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Humacyte, Inc. (HUMA) closed at $1.06 in the latest trading session, marking a -1.85% move from the prior day.
Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Humacyte, Inc. (HUMA) stood at $0.84, denoting a +2.66% move from the preceding trading day.
Humacyte, Inc. (HUMA) Discusses Unmet Needs and Advances in Dialysis Access with ATEV for Hemodialysis Patients Transcript
Humacyte, Inc. (HUMA) Discusses Unmet Needs and Advances in Dialysis Access with ATEV for Hemodialysis Patients Transcript
